Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.
Colorectal cancer
noninvasive
stool DNA test
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
29 01 2021
29 01 2021
Historique:
received:
06
06
2020
revised:
01
12
2020
accepted:
24
12
2020
pubmed:
5
1
2021
medline:
16
12
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
Despite the steadily increasing worldwide incidence of colorectal cancer (CRC), an effective noninvasive approach for early detection of CRC is still under investigation. The guaiac-based fecal occult blood test (FOBT) and fecal immunochemical test (FIT) have gained popularity as noninvasive CRC screening tests owing to their convenience and relatively low costs. However, the FOBT and FIT have limited sensitivity and specificity. To develop a noninvasive tool for the detection of CRC, we investigated the sensitivity, specificity, and accuracy of a stool DNA test targeting methylated syndecan-2 (SDC2), which is frequently methylated in patients with CRC. The present study enrolled 62 patients diagnosed as having stage 0-IV CRC and 76 healthy participants between July 2018 and June 2019 from two institutions. Approximately 4.5 g of stool sample was collected from each participant for detection of human methylated SDC2 gene. In total, 48 of 62 (77.4%) patients with CRC showed positive results, whereas 67 out of 76 (88.2%) healthy participants showed negative results. The area under the curve of the receiver operating characteristic curve constructed was 0.872 for discrimination between patients with CRC and healthy individuals. The present study highlights the potential of the fecal methylated SDC2 test as a noninvasive detection method for CRC screening with a relatively favorable sensitivity of 77.4%, a specificity of 88.2% and a positive predictive value of 84.2% compared with other available fecal tests. Further multicenter clinical trials comprising subjects of varied ethnicities are required to validate this test for the mass screening of patients with CRC.
Identifiants
pubmed: 33393623
pii: 227461
doi: 10.1042/BSR20201930
pmc: PMC7809545
pii:
doi:
Substances chimiques
SDC2 protein, human
0
Syndecan-2
149769-25-5
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 The Author(s).
Références
Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
Gastroenterology. 2009 Feb;136(2):459-70
pubmed: 19026650
Gastroenterology. 2016 Sep;151(3):427-439.e6
pubmed: 27311556
Can J Gastroenterol. 2013 Aug;27(8):467-75
pubmed: 23936877
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Am J Gastroenterol. 2017 Nov;112(11):1728-1735
pubmed: 29016558
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Front Oncol. 2013 May 13;3:114
pubmed: 23717813
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
J Natl Cancer Inst. 2010 Jan 20;102(2):89-95
pubmed: 20042716
J Gen Intern Med. 2008 Feb;23(2):169-74
pubmed: 18157581
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
N Engl J Med. 2014 Apr 3;370(14):1287-97
pubmed: 24645800
Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1411-1419
pubmed: 28619831
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
CA Cancer J Clin. 2008 May-Jun;58(3):130-60
pubmed: 18322143
Ann Intern Med. 1997 May 15;126(10):811-22
pubmed: 9148658
Mol Biol Res Commun. 2016 Mar;5(1):49-57
pubmed: 27844020
J Cancer. 2019 Aug 28;10(21):5264-5271
pubmed: 31602277
Abdom Radiol (NY). 2016 Aug;41(8):1441-4
pubmed: 27259335
Am J Prev Med. 2012 Dec;43(6):573-83
pubmed: 23159252
J Mol Diagn. 2013 Jul;15(4):498-507
pubmed: 23747112
Med Care. 2008 Sep;46(9 Suppl 1):S10-6
pubmed: 18725820
CA Cancer J Clin. 2015 Jan-Feb;65(1):30-54
pubmed: 25581023
Cancer. 2010 Feb 1;116(3):544-73
pubmed: 19998273
Arch Intern Med. 2012 Apr 9;172(7):575-82
pubmed: 22493463
MMWR Morb Mortal Wkly Rep. 2015 Dec 18;64(49):1353-8
pubmed: 26678069
BMJ Open Gastroenterol. 2019 May 4;6(1):e000293
pubmed: 31275586
Gastroenterology. 2012 Dec;143(6):1442-1460.e1
pubmed: 23000599
Gut. 2019 Sep;68(9):1642-1652
pubmed: 30538097
BMC Cancer. 2014 Jan 31;14:54
pubmed: 24485021
Prev Med. 2009 Nov;49(5):442-8
pubmed: 19747502
Clin Epigenetics. 2019 Mar 15;11(1):51
pubmed: 30876480
World J Gastroenterol. 2015 Sep 21;21(35):10057-61
pubmed: 26401070
Int J Cancer. 2019 Jun 15;144(12):2992-3000
pubmed: 30536395
Prev Med. 2020 Jan 27;133:106003
pubmed: 32001308
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597